Curaleaf Holdings (CURLF) Income from Continuing Operations (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Income from Continuing Operations of 127334000.0 for Q1 2026, down 838.04% year-on-year from 17253000.0 in Q1 2025, and up 46.7% on a QoQ basis from 238908000.0 in Q4 2025.
Curaleaf Holdings (CURLF) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Income from Continuing Operations for 8 consecutive years, with 127334000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations fell 838.04% year-over-year to 127334000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 348152000.0 (down 56.13% YoY) and the FY2025 annual result came in at 201903000.0, up 4.59% from the prior year.
- Income from Continuing Operations climbed to 127334000.0 in Q1 2026 per CURLF's latest filing, from 238908000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for CURLF reached as high as 81059000.0 in Q2 2022 and fell as low as 63600000000.0 in Q4 2023.
- A 5-year average of 3771960117.65 and a median of 14229000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 26884.25% — and 2024, when it soared 607.67%.
- Year by year, Income from Continuing Operations stood at 235693000.0 in 2022, then sank by 26884.25% to 63600000000.0 in 2023, then surged by 99.57% to 275257000.0 in 2024, then gained by 13.21% to 238908000.0 in 2025, then jumped by 46.7% to 127334000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 127334000.0, 238908000.0, and 5930000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | -127.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.33 Mn |
| Dec 31, 2025 | -238.91 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 12.16 Mn |
| Mar 31, 2025 | 17.25 Mn |
| Dec 31, 2024 | -275.26 Mn |
| Sep 30, 2024 | 20.78 Mn |
| Jun 30, 2024 | 14.23 Mn |
| Mar 31, 2024 | 28.60 Mn |
| Dec 31, 2023 | -63.60 Bn |
| Sep 30, 2023 | -4.09 Mn |
| Jun 30, 2023 | 17.31 Mn |
| Mar 31, 2023 | 37.58 Mn |
| Dec 31, 2022 | -235.69 Mn |
| Sep 30, 2022 | 58.52 Mn |
| Jun 30, 2022 | 81.06 Mn |
| Mar 31, 2022 | 64.53 Mn |
| Dec 31, 2021 | -5.24 Mn |
| Sep 30, 2021 | 62.95 Mn |
| Jun 30, 2021 | 76.97 Mn |